Understanding how chromosomal changes affect treatment responses in neuroblastoma
Dissecting the mechanisms by which chromosomal instability impacts anti-Disialoganglioside responses in neuroblastoma
This study is looking at how certain changes in the genes of children with neuroblastoma might affect how well they respond to a specific treatment called anti-GD2 therapy, which can help them but also has some tough side effects, so the goal is to find ways to predict who will benefit the most from it.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-10875548 on NIH RePORTER |
What this research studies
This research investigates how chromosomal instability in neuroblastoma affects children's responses to anti-GD2 therapy, a treatment that has improved survival rates but comes with significant side effects. The study aims to identify predictive biomarkers that can help determine which patients are likely to benefit from this therapy. By analyzing genomic and transcriptomic data, researchers will develop a statistical model to predict treatment responses and explore the underlying mechanisms of these responses. This could lead to better treatment strategies tailored to individual patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are children aged 0-11 years diagnosed with high-risk neuroblastoma who are being considered for anti-GD2 therapy.
Not a fit: Patients with neuroblastoma who are not eligible for anti-GD2 therapy or are older than 11 years may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized treatment options for children with high-risk neuroblastoma.
How similar studies have performed: Previous research has shown promise in identifying biomarkers for cancer treatment responses, suggesting that this approach could yield valuable insights.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Rebernick, Ryan — University of Michigan at Ann Arbor
- Study coordinator: Rebernick, Ryan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.